Headaches in pregnancy by unknown
Drugs and pregnancy
Most drugs cross the placenta and have the potential to
adversely affect the fetus, and, although studies have not
absolutely established the safety of any medication during
pregnancy, some are believed to be relatively safe [1].
Adverse drug effects depend on the dose and route of
administration, concomitant exposures and the timing of
the exposure relative to the period of development. Death
to the conceptus, teratogenicity, foetal growth abnormali-
ties, perinatal effects, postnatal developmental abnormali-
ties, delayed oncogenesis, and functional and behavioural
changes can result from drugs or other agents (Table 1) [2].
The FDA has five categories of labelling for drug use
in pregnancy [3–5]. An alternate rating system is TERIS,
an automated teratogen information resource wherein the
rating for each drug or agent is based on a consensus of
expert opinion and the literature [6]. The FDA categories
have little, if any, correlation to the TERIS teratogenic
risk. This discrepancy results in part from the fact that the
FDA categories were designed to provide therapeutic
guidance and the TERIS ratings are useful for estimating
the teratogenic risks of a drug and not vice versa [7].
Headache treatment
The major concerns in the management of the pregnant
patient are the effects of both the medication and the dis-
ease on the fetus. Because of the possible risk of injury to
the fetus, medication use should be limited; however, it is
not contraindicated during pregnancy [4, 8]. Because
migraine usually improves after the first trimester, many
women can manage their headaches with this reassurance
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Abstract Most women with
migraine improve during pregnancy.
Some women have their first attack.
Migraine often recurs postpartum
and can begin for the first time.
Drugs are commonly used during
pregnancy despite insufficient
knowledge about their effects on
the growing fetus. Most drugs are
not teratogenic. Adverse effects,
such as spontaneous abortion,
developmental defects and various
postnatal effects depend on the dose
and route of administration and the
timing of the exposure relative to
the period of foetal development.
While medication use should be
limited, it is not absolutely con-
traindicated in pregnancy.
Nonpharmacologic treatment is the
ideal solution; however, analgesics
such as acetaminophen and opioids
can be used on a limited basis.
Preventive therapy is a last resort.
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and nonpharmacologic means of coping, such as ice, mas-
sage and biofeedback [4, 9]. Some women, however, will
continue to have severe, intractable headaches, sometimes
associated with nausea, vomiting and possible dehydra-
tion. These conditions may pose a risk to the fetus that is
greater than the potential risk of the medications used to
treat the pregnant patient [8, 9].
Symptomatic treatment, designed to reduce the severi-
ty and duration of symptoms, is used to treat an acute
headache attack. Individual attacks should be treated with
rest, reassurance and ice packs. Symptomatic drugs are
indicated for headaches that do not respond to nonphar-
macologic treatment. The NSAIDs, acetaminophen (alone
or with codeine), codeine alone or other opioids can be
used during pregnancy [10]. Aspirin in low intermittent
doses is not a significant teratogenic risk, although large
doses, especially if taken near term, may be associated
with maternal and fetal bleeding. Aspirin use should prob-
ably be reserved unless there is a definite therapeutic need
for it (other than headache). In general, NSAIDs may be
safely taken for pain during the first trimester of pregnan-
cy. However, their use should be limited during later preg-
nancy, as some NSAIDs may constrict or close the fetal
ductus arteriosus [10]. Barbiturate and benzodiazepine
use should be limited. Ergotamine, dihydroergotamine
(DHE) and triptans should be avoided [4, 9]. However,
Reiff-Eldridge et al. [11] recently reviewed the Glaxo-
Wellcome pregnancy registries and found that sumatriptan
did not provide a risk estimate exceeding that expected in
the disorder treated, and no pattern of defects has been
observed.
The associated symptoms of migraine, such as nausea
and vomiting, can be as disabling as the headache pain
itself. In addition, some medications that are used to treat
migraine can produce nausea. Metoclopramide, which
decreases the gastric atony seen with migraine and
enhances the absorption of coadministered medications, is
extremely useful in migraine treatment [12]. Mild nausea
can be treated with phosphorylated carbohydrate solution
(emetrol) or doxylamine succinate and vitamin B6 (pyri-
doxine) [10, 12]. More severe nausea may require the use
of injections or suppositories. Trimethobenzamide, chlor-
promazine, prochlorperazine and promethazine are avail-
able orally, parenterally and as a suppository, and can all
be used safely. We frequently use promethazine and
prochlorperazine suppositories. Corticosteroids can be
utilised occasionally. Some use prednisone in preference
to dexamethasone (which crosses the placenta more read-
ily). Domperidone is an antiemetic used outside the
United States. In the United Kingdom [13] its use is not
advised during pregnancy, because of variable embry-
otoxic effects in animal tests. Severe acute attacks of
migraine should be treated aggressively. We start IV flu-
ids for hydration and then use prochlorperazine 10 mg IV
to control both nausea and head pain. IV opioids or IV
corticosteroids can supplement this.
Preventive treatment
Increased frequency and severity of migraine associated
with nausea and vomiting may justify the use of daily pro-
phylactic medication. This treatment option should be a
last resort. Preventive therapy is designed to reduce the
frequency and severity of headache attacks. Prophylaxis
should be considered when patients experience at least
three or four prolonged, severe attacks a month that are
particularly incapacitating or unresponsive to symptomatic
therapy and may result in dehydration and fetal distress [9,
14]. Beta-adrenergic blockers such as propranolol have
been used under these circumstances, although adverse
effects, including intrauterine growth retardation, have
been reported [10, 12, 14]. If the patient has a coexistent
illness that requires treatment, one drug that will treat both
disorders should be chosen. For example, propranolol [10]
can be used to treat hypertension and migraine while flu-
oxetine can be used to treat comorbid depression.
Table 1 Definitions and drug effects
Spontaneous abortion Death of the conceptus. Most due to chromosomal abnormality
Embryotoxicity The ability of drugs to kill the developing embryo
Congenital anomalies Deviation from normal morphology or function
Teratogenicity The ability of an exogenous agent to produce a permanent abnormality of structure 
or function in an organism exposed during embryogenesis or fetal life
Fetal effects Growth retardation, abnormal histogenesis (also congenital abnormalities and fetal death) 
The main outcome of fetal drug toxicity during the second and third trimesters of pregnancy
Perinatal effects Effects on uterine contraction, neonatal withdrawal or haemostasis
Postnatal effects Drugs may have delayed long-term effects: delayed oncogenesis, 
and functional and behavioural abnormalities
174
Drug exposure
If a woman inadvertently takes a drug while she is preg-
nant or becomes pregnant while taking a drug, determine
the dose, timing and duration of the exposure(s). Ascertain
the patient’s past and present state of health and the pres-
ence of mental retardation or chromosomal abnormalities
in the family. Using a reliable source of information (such
as TERIS), determine if the drug is a known teratogen
(although for many drugs this is not possible) [3, 6].
If the drug is teratogenic or the risk is unknown,
have the obstetrician confirm the gestational age by
ultrasound. If the exposure occurred during embryogen-
esis, then high-resolution ultrasound can be performed
to determine whether damage to specific organ systems
or structures has occurred. If the high-resolution ultra-
sound is normal, it is reasonable to reassure the patient
that the gross fetal structure is normal (within the
90% sensitivity of the study). However, fetal ultrasound
cannot exclude minor anomalies or guarantee the birth
of a normal child. Delays in achieving developmental
milestones, including cognitive development, are
potential risks that cannot be predicted or diagnosed
prenatally.
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